Agenus Publishes Seminal Study on Botensilimab's Activity in Treatment-Resistant Cancers

Stock Information for Agenus Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Agenus Inc.

Shareholders of Agenus Inc. Should Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights - AGEN
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GitLab, Agenus, and ZoomInfo and Encourages Investors to Contact the Firm
ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Agenus Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AGEN
Agenus Inc Is Being Sued For Possible Securities Fraud And Stockholders With Losses Are Urged To Contact The Schall Law Firm
Investors who lost money on Agenus Inc.(AGEN) should contact Levi & Korsinsky about pending Class Action - AGEN
ROSEN, LEADING INVESTOR COUNSEL, Encourages Agenus Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AGEN
Investors who lost money on Agenus Inc. (AGEN) should contact Levi & Korsinsky about pending Class Action - AGEN
Shareholders that lost money on Agenus Inc.(AGEN) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.